{"id":"NCT02149264","sponsor":"Ferring Pharmaceuticals","briefTitle":"A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males","officialTitle":"A Phase 3, Open-Label, Non-Randomized, Clinical Trial to Evaluate the Efficacy and Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07","primaryCompletion":"2015-05","completion":"2015-06","firstPosted":"2014-05-29","resultsPosted":"2017-07-28","lastUpdate":"2017-10-26"},"enrollment":160,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Adult Male Hypogonadism"],"interventions":[{"type":"DRUG","name":"Testosterone gel (FE 999303)","otherNames":[]}],"arms":[{"label":"Testosterone gel (FE 999303)","type":"EXPERIMENTAL"}],"summary":"This is a phase 3, open-label, non-randomized, clinical trial to evaluate the efficacy and safety of FE 999303 (Testosterone gel) in adult hypogonadal males.","primaryOutcome":{"measure":"The Percentage of Subjects Whose Average Concentration (Cave(0-24)) Serum Total Testosterone Levels Are ≥300 and ≤1050 ng/dL","timeFrame":"At Day 90","effectByArm":[{"arm":"Testosterone Gel (FE 999303)","deltaMin":76.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":22,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":159},"commonTop":["Bronchitis","Upper respiratory tract infection","Cough","Application site erythema","Nasopharyngitis"]}}